Is NeuroBo Pharmaceuticals Inc. (NRBO) A Solid Choice On The Value Front?

BEPC Stock
BEPC Stock

The stock of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) increased by $0.28 on Monday to finish at $0.56, up 101.30 percent. The last five days have seen an average of 18,239,900 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$0.6642. The average number of shares traded over the last 20 days was 4,620,075, while the average volume over the last 50 days totaled 1,902,722.

NRBO stock appreciated 38.95% since last month. On 08/31/22, the company’s shares reached a one-month low of $0.2465. The stock touched a high of $4.29 on 01/04/22, after rallying from a low of $0.25 in 52 weeks. The price of NRBO stock has declined by -54.44% or -$0.6642 this year, reaching a new high 2 times. Still, the stock price is down -87.04% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Financial Health

For the three months ended September 29, NeuroBo Pharmaceuticals Inc.’s quick ratio was 8.10, while its current ratio was 8.10, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $14000.0 and revenue of $15.3 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NRBO’s return on assets (ROA) during the last 12 months has been -117.40%. In the meantime, the return on equity (ROE) for the last 12 months was -137.10%.

Earnings Surprise

According to NeuroBo Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended September 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that NeuroBo Pharmaceuticals Inc.’s quarterly earnings would be -$0.16, but it ended up being -$0.18, beating the consensus by 11.10%. EBITDA was -$3.21 million for the quarter. Equity owned by shareholders amounts to $26.66 million.

Technical Picture

Here’s a quick look at NeuroBo Pharmaceuticals Inc.’s (NRBO) price momentum from a technical perspective. As of 12 September, the RSI 9-day stood at 76.22%, suggesting the stock is Overbought, with a 392.44% historical volatility rate.

The stochastic %K and %D were 34.34% and 30.27% respectively, while the average true range (ATR) was 0.0911. Based on the 14-day stochastic reading of 55.32%, the RSI (14) reading is 69.89%. On the 9-day MACD Oscillator, the stock is at 0.0340, and the 14-day reading is at 0.0161.

Analyst Ratings

In its analyst report released on June 15, 2020, H.C. Wainwright began covering NeuroBo Pharmaceuticals Inc. (NASDAQ: NRBO). The stock was rated as a Buy by the brokerage firm. Analysts have assigned NeuroBo Pharmaceuticals Inc. (NRBO) an Buy rating. NRBO is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.

What is NRBO’s price target for the next 12 months?

The current consensus forecast for the stock is between $16.00 and $16.00, with a median target price of $16.00. In analyzing these forecasts, the average price target given by analysts for NeuroBo Pharmaceuticals Inc. (NRBO) is $16.00.


Please enter your comment!
Please enter your name here